From Wikipedia, the free encyclopedia
|Molar mass||142.8 kg/mol|
|(what is this?)|
Ensituximab is a chimeric monoclonal antibody used in the treatment of cancers.
Ensituximab was developed by Neogenix Oncology, Inc.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Ensituximab" (PDF). American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|